TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00621231

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: 30 E% from protein
Study: NCT01262937

Intervention type: DEVICE
Intervention: Confocal Imaging
Description: Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)

Intervention type: DEVICE
Intervention: Confocal Imaging
Description: Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
Study: NCT04474457

Intervention type: DRUG
Intervention: Favipiravir
Description: Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir.
Study: NCT03540082

Intervention type: OTHER
Group type: OTHER
Intervention: Tuck and Roll Group
Description: An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fall Exposure
Description: An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
Study: NCT02934997

Intervention type: OTHER
Intervention: Observational study

Intervention type: OTHER
Intervention: Observational study
Study: NCT00216203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle
Study: NCT03001973

Intervention type: OTHER
Intervention: No Intervention
Description: Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
Study: NCT00005036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02661698

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oil: DHA enriched
Description: 3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 g capsules Placebo: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 g capsules Placebo: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oil: EPA enriched
Description: 3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
Study: NCT03660709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard-of-care HIV testing and counseling
Study: NCT04066660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligo Fucoidan
Description: 4.4 g oligo fucoidan powder, oral, BID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4.4 g placebo powder, oral, BID
Study: NCT01619111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemo- or endocrine therapy
Description: standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemo- or endocrine therapy + Lapatinib
Description: Lapatinib~+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)
Study: NCT01855698

Intervention type: OTHER
Intervention: Observation
Study: NCT04353596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor, angiotensin receptor blocker
Description: In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
Study: NCT00943774

Intervention type: OTHER
Intervention: Physiological maneuvers
Description: These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
Study: NCT00703001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: students in this arm will receive several oral health educational modules in class

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral Intervention
Description: Parents of enrolled children will receive assistance in accessing oral health care for their child
Study: NCT02912299

Intervention type: PROCEDURE
Intervention: Skin biopsies
Description: 2 3mm skin biopsies will be taken

Intervention type: PROCEDURE
Intervention: Skin biopsies
Description: 2 3mm skin biopsies will be taken

Intervention type: PROCEDURE
Intervention: Skin biopsies
Description: 2 3mm skin biopsies will be taken

Intervention type: OTHER
Intervention: Blood and urine analysis
Description: Measurement of sodium, potassium and kidneyfunction in blood and urine.

Intervention type: OTHER
Intervention: Blood and urine analysis
Description: Measurement of sodium, potassium and kidneyfunction in blood and urine.

Intervention type: OTHER
Intervention: Blood and urine analysis
Description: Measurement of sodium, potassium and kidneyfunction in blood and urine.

Intervention type: OTHER
Intervention: Blood collection for RNA-investigation
Description: A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.

Intervention type: OTHER
Intervention: Blood collection for RNA-investigation
Description: A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
Study: NCT01437657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching RO4917523 placebo orally daily, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 0.5 mg
Description: 0.5 mg orally daily, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 1.5 mg
Description: 1.5 mg orally daily, 6 weeks
Study: NCT04343742

Intervention type: DRUG
Intervention: chlorine dioxide 3000 ppm
Description: Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
Study: NCT01829958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT02912299

Intervention type: OTHER
Intervention: Blood collection for RNA-investigation
Description: A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
Study: NCT00125762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroScan
Study: NCT04092517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Corn Soya Diet
Description: Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Corn Moringa Diet
Description: Ingredients (% by weight): Maize (78.30); Moringa (20.0)
Study: NCT03686956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
Study: NCT02442726

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
Description: Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
Description: Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
Study: NCT03480412

Intervention type: PROCEDURE
Intervention: Follicular Phase
Description: The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.

Intervention type: PROCEDURE
Intervention: Luteal Phase
Description: Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
Study: NCT02334124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home
Description: The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ward
Description: Admission to a hospital based ward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 50mg/kg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flucloxacillin
Description: 50mg/kg 6 hourly
Study: NCT02905253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-084
Description: Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-084
Description: Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-084
Description: Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching AC-084 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching AC-084 capsules
Study: NCT02294084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each subject will receive a placebo (once a day) for 12 weeks.
Study: NCT00648804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Orally Disintegrating Tablets 8 mg
Description: 8mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran ODT® Tablets 8 mg
Description: 8mg, single dose fed
Study: NCT01313715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, one month interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, one month interval
Study: NCT03447938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MICS CABG
Description: Coronary artery bypass grafting performed through small incisions between the ribs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
Study: NCT00328744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: 18-month standard behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: 18-month standard behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Limited Variety
Description: Two chosen snack foods
Study: NCT03899363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: custom thermoplastic orthosis
Description: extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom thermoplastic orthosis
Description: extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
Study: NCT00646594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol (Advair)
Study: NCT00731055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo
Study: NCT05107804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise+CR
Description: Exercise with caloric-restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Conditioning
Description: Light Conditioning Exercise
Study: NCT01829958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment
Study: NCT03228823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone (Antiarrhythmic drug)
Description: AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
Study: NCT00910195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment with subsequent Bi-Level-APAP treatment
Description: CPAP treatment during the first night and then Bi-level-APAP treatment during second night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Level-APAP treatment with subsequent CPAP treatment
Description: Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
Study: NCT04236063

Intervention type: OTHER
Intervention: WHODAS 2.0 Questionnaire
Description: 36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
Study: NCT01892306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP CBT
Description: The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Existing optimized pharmacotherapy as delivered by treating psychiatrist
Study: NCT01363388

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID for 84 days
Study: NCT04941677

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study: NCT00389038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Skills Training
Description: Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache Education
Description: Behavioral Treatment 2 (headache education)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
Study: NCT03256461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactate clearance 10% target group
Description: Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactate clearance 20% target group
Description: Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard EGDT group
Description: Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
Study: NCT00981110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUAGEL Ag Hydrofiber Wound Dressing
Description: Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
Study: NCT01363388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: BID for 84 days